Results 41 to 50 of about 5,926 (192)

Case Report: Progressive disease of BRCA2-mutant colon adenocarcinoma following talazoparib therapy

Frontiers in Oncology, 2023
Colorectal cancer (CRC) is currently one of the most common tumor types diagnosed worldwide. In the early stages, the disease responds well to surgical and chemotherapeutic treatment, but in the later stages when therapeutic options are exhausted ...
Elizaveta Polyanskaya, Alexandra Lebedeva, Olesya Kuznetsova, Olesya Kuznetsova, Ekaterina Belova, Ekaterina Belova, Alexandra Kavun, Maxim Ivanov, Maxim Ivanov, Mikhail Fedyanin, Mikhail Fedyanin, Mikhail Fedyanin, Alexey Tryakin, Vladislav Mileyko, Dmitry Nosov   +14 more
doaj   +1 more source

Comparison between talazoparib and conventional chemotherapy in the treatment of HER2-positive breast cancer patients: A retrospective study

Frontiers in Immunology, 2022
BackgroundThe benefits of talazoparib compared with conventional chemotherapy in HER2-negative advanced breast cancer (ABC) remain unclear.MethodsPatients older than 18 years, with a deleterious germline BRCA1/2 (gBRCA1/2) mutated, metastatic, or locally
Ning Wang, Xiaopeng Yu
doaj   +1 more source

Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes

Cells, 2022
Inhibitors (PARPi) of poly(ADP-ribose-)polymerase-1 (PARP1) are used in antitumor therapy; their cytotoxicity correlates with the efficiency of PARP1 trapping in cell chromatin.
Natalya Maluchenko, Darya Koshkina, Anna Korovina, Vasily Studitsky, Alexey Feofanov   +4 more
doaj   +1 more source

Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers

Clinical and Translational Radiation Oncology, 2020
Summary: PARP inhibitors have been shown to radiosensitize tumor cells in both in vitro and in vivo studies. This is a phase I study that aims to determine the safety, tolerability, and maximally tolerated dose of talazoparib, a PARP inhibitor, when ...
David S. Lakomy, Diana L. Urbauer, Shannon N. Westin, Lilie L. Lin   +3 more
doaj   +1 more source

Outcomes in clinically relevant patient subgroups from the EMBRACA study: Talazoparib vs physician’s choice standard-of-care chemotherapy [PDF]

, 2020
Background: Talazoparib is a poly(adenosine diphosphate-ribose) polymerase inhibitor that causes death in cells with breast cancer susceptibility gene 1 or 2 (BRCA1/2) mutations.Methods: EMBRACA (NCT01945775) was a randomized phase III study comparing ...
Diab, Sami, Rugo, Hope S, Mina, Lida A, Tudor, Iulia Cristina, Litton, Jennifer K., Blum, Joanne L, Woodward, Natasha E., Rugo, Hope S., Lee, Kyung-Hun, Gauthier, Eric, Martin, Miguel, Bhattacharyya, Helen, Quek, Ruben GW, Blum, Joanne L., Woodward, Natasha E, Hurvitz, Sara A., Fehrenbacher, Louis, Mina, Lida A., Eiermann, Wolfgang, Yerushalmi, Rinat, Quek, Ruben G.W., Gonçalves, Anthony, Goodwin, Annabel, Litton, Jennifer K, Hurvitz, Sara A, Ettl, Johannes   +25 more
core   +1 more source

Supplementary table 1.docx: A Phase I trial of talazoparib in patients witha dvanced hematologic malignancies

, 2021
Supplementary Figure 1. Dose linearity and proportionality in plasma following multiple doses of talazoparib. Supplementary material.
Adrian Bloor (3520115), Ajay K Gopal (11598880), Mark Juckett (11598895), Ying Chen (9697), Rakesh Popat (8859863), Terry Gaymes (11598889), Tobias Menne (11598886), Ryan J Mattison (11598883), Asim Khwaja (11598892), Matthew J Cotter (11598898), Ghulam J Mufti (9332201)   +10 more
core   +1 more source

Combination of Talazoparib and Calcitriol Enhanced Anticancer Effect in Triple−Negative Breast Cancer Cell Lines

Pharmaceuticals, 2022
Monotherapy for triple−negative breast cancer (TNBC) is often ineffective. This study aimed to investigate the effect of calcitriol and talazoparib combination on cell proliferation, migration, apoptosis and cell cycle in TNBC cell lines.
Fu Hou Wong, Vijayaraj Kumar Palanirajan, Edmond Siah Chye Ng, Chung Keat Tan, Eugenie Sin Sing Tan, Farahnaz Amini   +5 more
doaj   +1 more source

Talazoparib in BRCA-mutated advanced breast cancer: is earlier better? [PDF]

, 2022
Talazoparib is an oral PARP inhibitor approved for locally advanced/metastatic breast cancer. There is no consensus, however, as to whether it is better used as a first-line treatment or after other therapies in patients with gBRCA mutations.
Boulos, Mariana, Kourié, Hampig Raphaël, Nsouli, Ghazi, Tfayli, Arafat Hussein, Moujaess, Elissar   +4 more
core   +1 more source

Talazoparib and BKM-120 have different, complementary modes of action.

, 2016
(A) Lysates prepared from H1048 and H209 xenografts (3 per treatment group) harvested 2 hours after treatment on day 3 showed increased p-AKT (S473) and p-S6 (S240,244) with talazoparib treatment alone but reduced signaling with BKM-120 treatment alone ...
Robert J. Cardnell (2602669), Lixia Diao (184400), Yuqiao Shen (2128330), Seema Mukherjee (2602678), Fatemeh Masrorpour (2602666), Jing Wang (1228470), Lauren A. Byers (160314), C. Allison Stewart (2602663), YouHong Fan (2602672), Pan Tong (698977), John V. Heymach (160316), Monique Nilsson (2602675), Ying Feng (151159)   +12 more
core   +1 more source

Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review

Frontiers in Oncology, 2022
PARP inhibitors have recently emerged as a maintenance treatment option for metastatic pancreatic cancer patients with germline BRCA mutations. However, the possibility of PARP-inhibitor use as a standalone-targeted therapy for patients with various ...
Andrei Kachmazov, Larisa Bolotina, Anna Kornietskaya, Olesya Kuznetsova, Olesya Kuznetsova, Maxim Ivanov, Alexander Fedenko   +6 more
doaj   +1 more source